#ASCO21: Merck tacks on armor in early-line cancer fight with 2 Keytruda wins setting the tone
With more and more PD-(L)1 checkpoint inhibitors flooding the market, there has been a long-running war over which of those drugs can secure a lead in early-line patients. With Keytruda on top of the world, Merck is well-positioned to take the lead — and it’s rolling out a pair of studies targeted directly at that front.
As part of a broad plan of attack to bring I-O wonder drug Keytruda into earlier lines of metastatic cancer, Merck will unveil winning results at this year’s ASCO from Phase II and Phase III tests as part of combination therapies topping standard of care in non-small cell lung and gastric cancers.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters